СОВРЕМЕННОЕ ПРЕДСТАВЛЕНИЕ О ДИАГНОСТИКЕ РАКА ПРОСТАТЫ


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

В обзоре обобщены фактические данные об этиологии и диагностике рака простаты. В частности, отмечается, что по-прежнему комплексное урологическое обследование остается основным методом диагностики данного заболевания. Однако инвазивный характер исследований (пункционная мультифокальная тканевая биопсия простаты), их дороговизна и необходимость в специально подготовленном персонале делают актуальным поиск более современных и неинвазивных методов диагностики этого заболевания. Отмечается перспективность дальнейших исследований в этом направлении.

Полный текст

Доступ закрыт

Об авторах

Ю. Ю. Винник

ФГБОУ ВО КрасГМУ им. проф. В. Ф. Войно-Ясенецкого Минздрава России

Email: vinnik33@mail.ru
д.м.н., профессор кафедры урологии, андрологии и сексологии Красноярск, Россия

А. В. Андрейчиков

ФГБОУ ВО КрасГМУ им. проф. В. Ф. Войно-Ясенецкого Минздрава России

Email: andrei4ikov@yandex.ru
д.м.н., профессор кафедры урологии, андрологии и сексологии Красноярск, Россия

Н. Ю. Климов

КГБУЗ «Красноярский краевой клинический онкологический диспансер им. А. И. Крыжановского»

Email: scrubs22@yandex.ru
врач-уролог Красноярск, Россия

Список литературы

  1. Clinical oncourology. Ed. B.P. Matveev. M.: Izdatel’skii dom ABV-press. 2011. 934 p.
  2. Andreeva Yu.Yu., Danilova N.V., Moskvina L.V., Zavalishina L.E., Kekeeva T.V., Mal’kov P.G., Frank G.A. Tumors of the urinary system and male genital organs. Morphological diagnostics and genetics: A guide for doctors. M.: Prakticheskaya meditsina, 2014.
  3. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):359-386.
  4. American Cancer Society. Cancer Cancer Facts & Figures 2016. Atlanta: American Cancer Society. 2016;66 р.
  5. Apolikhin O.I., Sivkov A.V., Moskaleva N.G., Solntseva T.V., Komarova V.A. Analysis of the morbidity and mortality in the Russian Federation for a ten-year period (2002-2012) according to official statistics. Eksperimental’naya i idinicheskaya urologiya. 2014;2:4-
  6. Bashir M.N. Epidemiology of Prostate Cancer. Asian Pac J Cancer Prev. 2015;16(13):5137-5141.
  7. Ferlay J., Shin H.R., Bray F. et al. GLOBOCAN 2008 Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. accepted 2010.
  8. Becker N. Epidemiology of prostate cancer. Radiologe. 2011;51(11):922-999.
  9. Lopatkin N.A. A guide to urology. M.: Meditsina. 1998;3:368-520.
  10. Borkowski А., Borowka A. Choroby Gruczolu krokowego. Warszawa. 1997;396 s.
  11. Chissov V.I., Rusakov I.G. Incidence of prostate cancer in the Russian Federation. Eksperimental’naya i idinicheskaya urologiya. 2011;2-3:12.
  12. Yao S.L., Lu-Yao G. Understanding and appreciating overdiagnosis in the PSA era. J Natl Cancer Inst. 2002;94(13):958-960.
  13. Pal’tsev M.A., Kiselev V.I., Muizhnek E.L. Molecular targets in the prevention and treatment of prostate hyperplasia and prostate cancer. M.: Izd-vo Dimitreid Grafik Grupp. 2009;484 p.
  14. Bezrukov E.A. The choice of treatment for localized and locally advanced prostate cancer: Dr.Med.Sci. Thesis. M., 2008. 49 p.
  15. Eichler K., Hempel S., Wilby J., Myers L., Bachmann L.M., Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J. Urol. 2006; 175(5): 1605-1612.
  16. Raynaud J.P. Testosterone deficiency syndrome: treatment and cancer risk. J Steroid Biochem Mol Biol. 2009;114:96-105.
  17. Hsing A.W. Hormones and prostate cancer: what’s next? Epidemiol Rev. 2001;23:42-58.
  18. Mohr B.A., Feldman H.A., Kalish L.A., Longcope C., McKinlay J.B. Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study. Urology. 2001;57:930-935.
  19. Vatten L.J., Ursin G., Ross R.K., Stanczyk F.Z., Lobo R.A., Harvei S., Jellum E. Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol Biomarkers Prev. 1997;6:967-969.
  20. Spigelman S.S., McNeal J.E., Freiha F.S., Stamey T.A. Rectal examination in volume determination of carcinoma of the prostate: clinical and anatomical correlations. J. Urol. 1986; 136(6):1228-1230.
  21. Okotie O.T., Roehl K.A., Han M., Loeb S., Gashti S.N., Catalona W.J. Characteristics of prostate cancer detected by digital rectal examination only. Urology. 2007;70(6):1117-1120.
  22. Zubarev A.V., Alferov S.M., Gribunov Yu.P. Elastography in differential diagnosis of prostate diseases. Kremlevskaya meditsina klinicheskii vestnik. 2008;2:44-47.
  23. Braeckman J., Autier P., Zât’ura F., Peltier A., Romics I., Stenz} A., Emberton M. Evaluation of HistoScanning™ for the detection, location and volume estimation of prostate cancer: Results of the open phase of the PHS-02 study. J Clin Oncol. 2011;29 (Suppl. 7; abstr 55).
  24. Glybochko P.V., Alyaev Yu.G., Amosov A.V., Krupinov G.E., Obukhov A.A., Ganzha T.M., Novichkov N.D. Early diagnosis of prostate cancer by histoscanning. Andrologiya i genital’naya khirurgiya. 2014;2:37-43.
  25. Gazhonova V.E., Zubarev A.V. The possibilities of three-dimensional ultrasound angiography in monitoring changes in prostate cancer. Modern invasive and non-invasive methods of diagnosis. Ultrasound, electrophysiology. M.: Air-Art. 2000;229-32.
  26. Mazo E.B., Gazhonova V.E., Solov’ev V.V. Three-dimensional echography in the diagnosis and prediction in the treatment of prostate cancer. Vestnik RONTs im. N.N. Blokhina RAMN. 2008;19(1): 7-15.
  27. Hricak H., Choyke P.L., Eberhardt S.C., Leibel S.A., Scardino P.T. Imaging prostate cancer: a multidisciplinary perspective. Radiology. 2007;243:28-53.
  28. Roivainen A., Forsback S., Grönroos T., Lehikoinen P., Kähkönen M., Sutinen E., Minn H. Blood metabolism of [methyl-nC] choline: implications for in vivo imaging with positron emission tomography. Eur J Nucl Med. 2000;27:25-32.
  29. Portalez D., Rollin G., Leandri P., Elman B., Mouly P., Jonca F., Malavaud B. Prospective comparison of T2w-MRI and dynamic-contrast-enhanced MRI, 3D-MR spectroscopic imaging or diffusion-weighted MRI in repeat TRUS-guided biopsies. Eur. Radiol. 2010;20:2781-2790.
  30. Fütterer J.J., Verma S., Hambrock T., Yakar D., Barentsz J.O. Highrisk prostate cancer: value of multi-modality 3TMRI-guided biopsies after previous negative biopsies. Abdom. Imaging. 2012;37:892-896.
  31. Fütterer J.J., Heijmink S.W.,Scheenen T.W., Veltman J., Huisman H.J., Vos P., Hulsbergen-Van de Kaa C.A., Witjes J.A., Krabbe P.F., Heerschap A., Barentsz J.O. Prostate cancer localization with dynamic contrastenhanced. MR imaging and proton MR spectroscopic imaging. Radiology. 2006;241:449-458.
  32. Glybochko P.V., Alyaev Yu.G., Ternovoi S.K. et al. Diagnosis of local recurrence of prostate cancer after radical prostatectomy: native endorectal MRI and endorectal MRI with dynamic contrast. Meditsinskii vestnik Bashkortostana. 2013;8(2):249-256.
  33. Hara T., Kosaka N., Kishi H. Development of 18F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med. 2002;43:187-199.
  34. Scheidler J., Hricak H., Vigneron D.B., Yu K.K., Sokolov D.L., Huang L.R., Zaloudek C.J., Nelson S.J., Carroll P.R., Kurhanewicz J. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology. 1999;213:473-480.
  35. Yu K.K., Scheidler J., Hricak H., Vigneron D.B., Zaloudek C.J., Males R.G., Nelson S.J., Carroll P.R., Kurhanewicz J. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology. 1999;213:481-488.
  36. Rodriguez-Gonzalez A., Ramirez de Molina A., Fernandez F., Ramos M.A., del Carmen Nunez M., Campos J., Lacal J.C. Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells. Oncogene 2003;22:8803-12.
  37. White S., Hricak H., Forstner R., Kurhanewicz J., Vigneron D.B., Zaloudek C.J., Weiss J.M., Narayan P., Carroll P.R. Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images. Radi-ology. 1995;195:385-390.
  38. Kotzerke J., Gschwend J.E., Neumaier B. PET for prostate cancer imaging: still a quandary or the ultimate solution? J Nucl Med. 2002;43:200-202.
  39. Kotzerke J., Volkmer B.G., Glatting G., van den Hoff J., Gschwend J.E., Messer P., Reske S.N., Neumaier B. Intraindividual comparison of [uC]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin. 2003;42:25-30.
  40. Kotzerke J., Volkmer B.G., Neumaier B., Gschwend J.E., Hautmann R.E., Reske S.N. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2002;29:1380-1394.
  41. Diseases of the prostate. Ed. Alyaev Yu.G. M.: GEOTAR-Media. 2009;240 p
  42. National Institute for Health and Clinical Excellence (NICE) clinical guideline 58, Prostate Cancer: diagnosis and treatment, 2008.
  43. Hodge K.K., McNeal J.E., Terris M.K., Stamey T.A. Random systematic versus directed ultrasound guided transrectal cjre biopsies of the prostate. J. Urol. 1989;142:71-75.
  44. Antoniewicz A. Biopsja stercza. Torun, 2002. 123 s.
  45. Bono A.V. Strategy in negative prostate biopsy. Third International Galician Urological Meeting. Krakуw: Media Co-worker. 2000;2-5.
  46. Chappell B., McLoughlin J. Technical considerations when obtaining and interpreting prostatic biopsies from men wioth suspicion of early prostate cancer: Part I. BJU Int. 2005;95:1135-1140.
  47. Terris M.K., McNeal J.E., Stamey T.A. Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. J. Urol. 1992;148:829-832.
  48. Pushkar D.Yu., Govorov A.V. Prostate biopsy. M.: GEOTAR-Media. 2010. 208 p.
  49. Singh H., Canto E.I., Shariat S.F., Kadmon D., Miles B.J., Wheeler T.M., Slawin K.M. Six additional systematic lateral cores enhance sextantbiopsy prediction of pathological features at radical prostatectomy. J. Urol. 2004;171:204-209.
  50. Nash P.A., Bruce J.E., Indudhara R., Shinohara K. Transrectal ultrasound guided prostate nerve blockade eases systematic needle biopsy of the prostate. J. Urol. 1996;155:607-609.
  51. Elbe J.N., Sauter G. et al. eds. World Health Organization Classification of Tumors. Pathology and Genetics: Tumours of the urinary system and male genital organs / Lyon, France: IA RC Press, 2004. p. 179.
  52. Gurel B., Lucia M.S., Thompson I.M. Jr, Goodman P.J., Tangen C.M., Kristal A.R., Parnes H.L., Hoque A., Lippman S.M., Sutcliffe S., Peskoe S.B., Drake C.G., Nelson W.G., De Marzo A.M., Platz E.A. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer epidemiology biomarkers and prevention. 2014;56 p.
  53. Jones J.S. Saturation biopsy for detecting and characterizing prostate cancer. BJU. Int. 2007;99:1340-1344.
  54. Lane B.R., Zippe C.D., Abouassaly R., Schoenfield L., Magi-Galluzzi C., Jones J.S. Saturation technique does not decrease cancer detection during followup after initial prostate biopsy. J. Urol. 2008;179: 1746-1750.
  55. Roehl K.A., Antenor J.A., Catalona W.J. Serial biopsy results in prostate cancer screening study. J. Urol. 2002;167:2435-2439.
  56. Taira A.V.,Merrick G.S., Galbreath R.W.,Andreini H., Taubenslag W., Curtis R., Butler W.M., Adamovich E., Wallner K.E. Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. Prostate Cancer Prostatic Dis. 2010;13:71-77.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2017

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах